抗肿瘤抗体药物研究进展.PDFVIP

国际病理科学与临床杂志 2013, 33(2) Int J Path ol Clin Me d 155 DOI:10.3969/j.issn.1673-2588.2013.02.013 /gjblkx/fileup/PDF/201302155.pdf 抗肿瘤抗体药物的研究进展 陈琳 综述 李官成 审校 (中南大学肿瘤研究所；国家卫生和计划生育委员会癌变原理重点实验室；教育部癌变与侵袭原理重点实验室，长沙 410078) [摘　要] 随着生物科技的发展以及对抗体结构与功能的深入研究，抗肿瘤抗体药物历经了裸抗体、单克隆 抗体及其衍生物、基因工程抗体三个时代的发展。本文概述了抗肿瘤抗体药物的发展历程及现状、 抗肿瘤抗体药物的分类与特点，以及抗体药物治疗肿瘤的基本原理，并且对抗体药物由单一靶点 向多靶点、抗体高效小型化、抗体组学与抗体组药物等方向的发展趋势进行了展望。 [关键词] 肿瘤；抗体药物；单克隆抗体；基因工程抗体 Progress in anti-tumor antibody drugs CHEN Lin, LI Guancheng (Cancer Research Institution, Central South University; Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Key Laboratory of Carcinogenesis and Invasion, Ministry of Education, Changsha 410078, China) Abstract With the development of biotechnology and deep research of the structure and function of antibodies, the progress of anti-tumor antibody drugs can be summarized three stages: naked antibody, monoclonal antibody and its derivatives, and gene engineering antibody. This article ummarizes the progress and current situation of the anti-tumor antibody drugs, the types and characteristics of these drugs, and the basic principle of antibody drug treatment for tumor. In addition, the trends from a single target to multiple antibody targets, the efficiency and miniaturization of antibody drugs and the boom of antibodomic and antibodomic medicine are also discussed. Key words tumor; antibody drugs; monoclonal antibody; gene engineering antibody 抗体药物是以细胞工程技术和基因工程技术 排斥反应、感染性疾病和心血管疾病等的治疗， 为主体的抗体工程技术制备的药